Ta strona została przetłumaczona automatycznie i dokładność tłumaczenia nie jest gwarantowana. Proszę odnieść się do angielska wersja za tekst źródłowy.

An Observational Study of Mircera (Methoxy Polyethylene Glycol-epoetin Beta) in Patients With Renal Anemia

17 listopada 2015 zaktualizowane przez: Hoffmann-La Roche

Non-interventional Study to Investigate Hemoglobin Levels and Dose Over Time in the Daily Use of Mircera for Renal Anemia in Larger Centers, and to Detect Differences Between Standard of Care in the Centers

This observational study will investigate hemoglobin levels and Mircera (methoxy polyethyleneglycol-epoetin beta) dose over time in patients with chronic kidney disease, and compare standards of care between centers. Data from each patient will be collected over 12 months of Mircera therapy.

Przegląd badań

Status

Zakończony

Warunki

Interwencja / Leczenie

Typ studiów

Obserwacyjny

Zapisy (Rzeczywisty)

1580

Kontakty i lokalizacje

Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.

Lokalizacje studiów

  • Niemcy
      • Saarlouis, Niemcy, 66740

Kryteria uczestnictwa

Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.

Kryteria kwalifikacji

Wiek uprawniający do nauki

18 lat i starsze (Dorosły, Starszy dorosły)

Akceptuje zdrowych ochotników

Nie

Płeć kwalifikująca się do nauki

Wszystko

Metoda próbkowania

Próbka prawdopodobieństwa

Badana populacja

CKD patients treated with Mirecera at different medical centers

Opis

Inclusion Criteria:

  • adult patients, >/= 18 years of age
  • chronic kidney disease
  • informed consent for data transmission

Exclusion Criteria:

  • serious hematological or infectious disease
  • acute bleeding in the 16 weeks preceding data collection
  • participation in an interventional trial
  • female patients: pregnancy or breast-feeding

Plan studiów

Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.

Jak projektuje się badanie?

Szczegóły projektu

Kohorty i interwencje

Grupa / Kohorta
Interwencja / Leczenie
1
Lek: methoxy polyethylene glycol-ep [Mircera]
As prescribed by physician

Co mierzy badanie?

Podstawowe miary wyniku

Miara wyniku
Opis środka
Ramy czasowe
Percentage of Participants With at Least One Hemoglobin Value Outside the Target Range
Ramy czasowe: Month 0 to Month 12
Mean hemoglobin was calculated from measurements taken during the Evaluation Period (Month 0 to Month 12). The target hemoglobin range was 10 to 13 gram/deciliter (g/dL). Percentage of participants with at least one hemoglobin value less than (<) 10 g/dL or greater than (>) 13 g/dL during the evaluation period by predialysis/hemodialysis is presented.
Month 0 to Month 12
Percentage of Participants With Hemoglobin Values Within Pre-defined Ranges During Evaluation Period by Dose Modification, Age, and Center Size
Ramy czasowe: Month 0 to Month 12
The percentage of participants with hemoglobin (Hb) values within the pre-defined ranges (10-12 g/dL, 11-12 g/dL, and 11-13 g/dL) during evaluation period (Month 0 to Month 12) by dose modification (yes or no), age (<65 years, greater than or equal to [>=] 65 years) and center size (>100 participants, less than or equal to [<=] 100 participants) is presented.
Month 0 to Month 12
Percentage of Participants With Hemoglobin Values Within Pre-defined Ranges During Month 6 to Month 12 by Dose Modification, Age, and Center Size
Ramy czasowe: Month 6 to Month 12
The percentage of participants with hemoglobin values within the pre-defined ranges (10-12 g/dL, 11-12 g/dL, and 11-13 g/dL) during Month 6 to Month 12 by dose modification (yes or no), age (<65 years, >=65 years) and center size (>100 participants, <=100 participants) is presented.
Month 6 to Month 12
Maximum Intra-Individual Fluctuation of Hemoglobin Values by Predialysis/Hemodialysis, Age, and Center Size
Ramy czasowe: Month 0 to Month 12
For characterization of intra-individual fluctuations, the maximum absolute differences were derived from study period specific individual mean values. Maximum intra-individual fluctuation of hemoglobin values by predialysis/hemodialysis, age (<65 years, >=65 years), and center size (>100 participants, <=100 participants) is presented. Data for this outcome measure was reported for overall participants.
Month 0 to Month 12
Serum Ferritin Values
Ramy czasowe: Months 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, and 12
Serum ferritin levels were measured as nanogram/milliliter (ng/mL). Data for this outcome measure was reported for overall participants.
Months 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, and 12
Serum Iron Values
Ramy czasowe: Months 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, and 12
Serum iron levels were measured as microgram/deciliter (mcg/dL). Data for this outcome measure was reported for overall participants.
Months 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, and 12
Transferrin Values
Ramy czasowe: Months 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, and 12
Transferrin levels were measured as milligram/deciliter (mg/dL). Data for this outcome measure was reported for overall participants.
Months 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, and 12
Transferrin Saturation Values
Ramy czasowe: Months 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, and 12
Transferrin saturation (TSAT) measured as a percentage, is a medical laboratory test. It is the ratio of serum iron and total iron-binding capacity, multiplied by 100. Data for this outcome measure was reported for overall participants.
Months 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, and 12
C-reactive Protein (CRP) Values
Ramy czasowe: Months 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, and 12
The test for CRP is a laboratory measurement for evaluation of an acute phase reactant of inflammation through the use of an ultrasensitive assay. A decrease in the level of CRP indicates reduction in inflammation and therefore improvement. Data for this outcome measure was reported for overall participants.
Months 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, and 12
Number of Physicians Satisfied With Treatment at Final Visit
Ramy czasowe: Month 12 or early discontinuation
Physicians were asked to rate their satisfaction with the methoxy polyethyleneglycol-epoetin beta treatment at final visit. Physicians' responses were "very satisfied", "satisfied", "undecided", or "not satisfied". One physician could analyze multiple participants but for the purpose of analysis each physician was counted as one for each analyzed participants; hence, the number of physicians (as per this assessment) was equal to the number of participants analyzed. Data for this outcome measure was reported for overall participants.
Month 12 or early discontinuation
Number of Participants Who Continued Treatment With Methoxy Polyethyleneglycol-epoetin Beta After Study Completion
Ramy czasowe: Month 12 or early discontinuation
At final visit, physicians were asked to answer ("yes" or "no") the question, whether they would continue treatment with methoxy polyethyleneglycol-epoetin beta treatment after study completion. Data for this outcome measure was reported for overall participants.
Month 12 or early discontinuation
Number of Participants With Reasons for Discontinuation of Methoxy Polyethyleneglycol-epoetin Beta Treatment After Study Completion
Ramy czasowe: Month 12 or early discontinuation
At final visit, physicians were asked to state the reasons in case of discontinuation of treatment with methoxy polyethyleneglycol-epoetin beta. The same participant could have discontinued treatment due to multiple reasons. Data for this outcome measure was reported for overall participants.
Month 12 or early discontinuation
Number of Participants Who Switched to Other Erythropoiesis Stimulating Agents (ESA)-Therapy
Ramy czasowe: Month 12 or early discontinuation
Number of participants who switched to other ESA therapies including Aranesp, Biopoin, Biosimilar, Erypo, and NeoRecormon is presented. Data for this outcome measure was reported for overall participants.
Month 12 or early discontinuation
Number of Participants Satisfied With Treatment at Final Visit
Ramy czasowe: Month 12 or early discontinuation
Participants were asked to rate their satisfaction with methoxy polyethyleneglycol-epoetin beta treatment at final visit. Participants' responses were "very satisfied", "satisfied", "undecided", or "not satisfied". Data for this outcome measure was reported for overall participants.
Month 12 or early discontinuation

Miary wyników drugorzędnych

Miara wyniku
Opis środka
Ramy czasowe
Average Methoxy Polyethylene Glycol-epoetin Beta Dose
Ramy czasowe: Months 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, and 12
Average methoxy polyethylene glycol-epoetin beta dose per application is presented by study month. Mean values were taken when more than 1 application was documented for a participant during the time period considered. Data for this outcome measure was reported for overall participants.
Months 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, and 12

Współpracownicy i badacze

Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.

Sponsor

Hoffmann-La Roche

Daty zapisu na studia

Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.

Główne daty studiów

Rozpoczęcie studiów

1 marca 2010

Zakończenie podstawowe (Rzeczywisty)

1 lutego 2013

Ukończenie studiów (Rzeczywisty)

1 lutego 2013

Daty rejestracji na studia

Pierwszy przesłany

15 stycznia 2010

Pierwszy przesłany, który spełnia kryteria kontroli jakości

15 stycznia 2010

Pierwszy wysłany (Oszacować)

18 stycznia 2010

Aktualizacje rekordów badań

Ostatnia wysłana aktualizacja (Oszacować)

18 grudnia 2015

Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości

17 listopada 2015

Ostatnia weryfikacja

1 listopada 2015

Więcej informacji

Terminy związane z tym badaniem

Dodatkowe istotne warunki MeSH

Inne numery identyfikacyjne badania

  • ML22714

Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .

Subskrybuj